Aisa Longnecker, Cristina M Foschi, Valerie M Carlberg, Lisa Swanson, Kristen E Holland
{"title":"Spesolimab成功治疗2例幼儿广泛性脓疱性银屑病。","authors":"Aisa Longnecker, Cristina M Foschi, Valerie M Carlberg, Lisa Swanson, Kristen E Holland","doi":"10.1111/pde.70043","DOIUrl":null,"url":null,"abstract":"<p><p>Spesolimab is an IL-36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5-year-old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin-36 receptor antagonist (DITRA) as well as a 6-year-old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.</p>","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children.\",\"authors\":\"Aisa Longnecker, Cristina M Foschi, Valerie M Carlberg, Lisa Swanson, Kristen E Holland\",\"doi\":\"10.1111/pde.70043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Spesolimab is an IL-36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5-year-old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin-36 receptor antagonist (DITRA) as well as a 6-year-old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.</p>\",\"PeriodicalId\":19819,\"journal\":{\"name\":\"Pediatric Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/pde.70043\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.70043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children.
Spesolimab is an IL-36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5-year-old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin-36 receptor antagonist (DITRA) as well as a 6-year-old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.
期刊介绍:
Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.